The Impact of Body Weight on Clinical and Immunological Outcomes in Relapse-Remitting Multiple Sclerosis Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt, 1053
- Nasser Institute For Research and Treatment
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age between 18 and 50 years at time of signing informed consent form.
- Relapsing- remitting multiple sclerosis as per the McDonald 2017 criteria, including an MRI brain satisfying the 2017 radiological criteria.
- Kurtzke EDSS step 0.0 - 6.0.
- At the time of screening, being treated with a stable dose of Interferon Beta 1a for at least 6 months.
Exclusion Criteria:
- they had been treated in the last 30 days with methylprednisolone
- they had changed their IFN-β preparation within the last 18 months
- they had other chronic diseases associated with MS
- they had been previously treated with immunosuppressive agents
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group 1
RRMS patients who received Interferon beta 1a and have normal weight
|
5 ml of blood samples were withdrawn from RRMS patients
|
|
Group 2
RRMS patients who received Interferon beta 1a and have are obese
|
5 ml of blood samples were withdrawn from RRMS patients
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between IL17 levels and patients' response to interferon beta 1a as measured by ELISA
Time Frame: Patients were treated with INF B 1a for at least 6 months
|
Anti-inflammatory and disease activity biomarkers
|
Patients were treated with INF B 1a for at least 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between IL 22 levels and patients' response to interferon beta 1a, measured by ELISA
Time Frame: Patients were treated with INF B 1a for at least 6 months
|
Anti-inflammatory and disease activity biomarkers
|
Patients were treated with INF B 1a for at least 6 months
|
|
Correlation between Expanded Disability Status Scale and patients' response to interferon beta 1a
Time Frame: Patients were treated with INF B 1a for at least 6 months
|
Determination disability level (0 - 6), The lowest value means that it is best outcome and the highest value is the worst outcome.
|
Patients were treated with INF B 1a for at least 6 months
|
|
Correlation between malondialdehyde levels and patients' response to interferon beta 1a
Time Frame: Patients were treated with INF B 1a for at least 6 months
|
oxidative stress biomarkers
|
Patients were treated with INF B 1a for at least 6 months
|
|
Correlation between MRI load and Patients' response to interferon beta 1a
Time Frame: Patients were treated with INF B 1a for at least 6 months
|
Determination of T2 lesions
|
Patients were treated with INF B 1a for at least 6 months
|
|
Correlation between body mass index and patients' response to interferon beta 1 a
Time Frame: Patients were treated with INF B 1a for at least 6 months
|
Body weight measurement
|
Patients were treated with INF B 1a for at least 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 2009 Jun;8(6):545-59. doi: 10.1016/S1474-4422(09)70082-1.
- Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000 Jun;47(6):707-17. doi: 10.1002/1531-8249(200006)47:63.0.co;2-q.
- Hesse D, Krakauer M, Lund H, Sondergaard HB, Langkilde A, Ryder LP, Sorensen PS, Sellebjerg F. Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response. Neurology. 2010 May 4;74(18):1455-62. doi: 10.1212/WNL.0b013e3181dc1a94.
- Axtell RC, Raman C, Steinman L. Interferon-beta exacerbates Th17-mediated inflammatory disease. Trends Immunol. 2011 Jun;32(6):272-7. doi: 10.1016/j.it.2011.03.008. Epub 2011 Apr 29.
- Brucklacher-Waldert V, Stuerner K, Kolster M, Wolthausen J, Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain. 2009 Dec;132(Pt 12):3329-41. doi: 10.1093/brain/awp289.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MSINF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.